ADTX

distress 8/10 · high distress / dilution risk

$0.00+7%today-100% from 52w high

aditxt.com26 employeesFounded 2017Mountain View, CABiotechnology

Revenue

pre-revenue

Liquidity

$0M

Runway

0.0 yrs

Shares 1y

-84%

Price & events

-100.0% over 6M

CatalystRating changeDilutionFinancingdashed = today

+6.7%

-92.4%

-100.0%

All

Overview

Market Cap: $2.61K
Volume: 507.59K
52 Week Range: $0.00 – $30754
Total Shares: 815.92K
Float Shares: 181.61K
Short %: 34.50%
% Held by Insiders: 0.06%
% Held by Institutions: 0.00%
RVOL: 0.00x

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 2

2026-06-10partnershipIgnite Proteomics, subsidiary of Aditxt, entered Business Combination Agreement with Copley Acquisition Corp SPAC to merge and become publicly traded.SEC 8-K
2025-05-19withdrawalTerminated arrangement agreement with Appili Therapeutics; effective May 31, 2025; eliminates ~$16M closing obligations.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 815,921 · 3 offerings/1y · 5 PIPEs

2026-07-178-Kprivate_placement
2026-06-238-Kprivate_placement
2026-06-108-Kmaterial_agreement
2026-06-098-Kprivate_placement
2026-04-23424B3offering
2026-04-21EFFECTshelf_effective
2026-04-148-Kmaterial_agreement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified